{"corpus_id":18238751,"paper_sha":"cfba141d239deb4bdb4989fdae0a91e6d7816225","doi":"10.1371/journal.pone.0074415","arxiv_id":null,"pmid":24069311,"pmcid":"3775786","mag_id":2125542684,"dblp_id":null,"acl_id":null,"title":"Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells","year":2013,"publication_date":"2013-09-17","venue":"PLoS ONE","journal":{"name":"PLoS ONE","pages":null,"volume":"8"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Biology","Medicine"],"reference_count":60,"citation_count":51,"influential_citation_count":2,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adenosine Triphosphatases","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":false,"ui":"Q000037"},{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D000251"},{"d":"Apoptosis","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D017209"},{"d":"Caspases","mj":false,"qs":[{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D020169"},{"d":"Cell Line, Tumor","mj":false,"ui":"D045744"},{"d":"Cell Survival","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D002470"},{"d":"Endoplasmic Reticulum","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"},{"q":"metabolism","mj":false,"ui":"Q000378"},{"q":"ultrastructure","mj":false,"ui":"Q000648"}],"ui":"D004721"},{"d":"Enzyme Inhibitors","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"},{"q":"toxicity","mj":false,"ui":"Q000633"}],"ui":"D004791"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Multiple Myeloma","mj":false,"qs":[{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D009101"},{"d":"Nuclear Proteins","mj":false,"qs":[{"q":"antagonists & inhibitors","mj":false,"ui":"Q000037"},{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D009687"},{"d":"Proteasome Endopeptidase Complex","mj":false,"qs":[{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D046988"},{"d":"Proteasome Inhibitors","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"},{"q":"toxicity","mj":false,"ui":"Q000633"}],"ui":"D061988"},{"d":"Protein Biosynthesis","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D014176"},{"d":"Proteolysis","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D059748"},{"d":"Signal Transduction","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D015398"}],"chemicals":[{"n":"Enzyme Inhibitors","ui":"D004791","reg":"0"},{"n":"Nuclear Proteins","ui":"D009687","reg":"0"},{"n":"Proteasome Inhibitors","ui":"D061988","reg":"0"},{"n":"Caspases","ui":"D020169","reg":"EC 3.4.22.-"},{"n":"Proteasome Endopeptidase Complex","ui":"D046988","reg":"EC 3.4.25.1"},{"n":"Adenosine Triphosphatases","ui":"D000251","reg":"EC 3.6.1.-"},{"n":"p97 ATPase","ui":"C404942","reg":"EC 3.6.1.-"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0074415&type=printable","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/cfba141d239deb4bdb4989fdae0a91e6d7816225","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Inhibition of the proteasome is a widely used strategy for treating multiple myeloma that takes advantage of the heavy secretory load that multiple myeloma cells (MMCs) have to deal with. Resistance of MMCs to proteasome inhibition has been linked to incomplete disruption of proteasomal endoplasmic-reticulum (ER)-associated degradation (ERAD) and activation of non-proteasomal protein degradation pathways. The ATPase p97 (VCP/Cdc48) has key roles in mediating both ERAD and non-proteasomal protein degradation and can be targeted pharmacologically by small molecule inhibition. In this study, we compared the effects of p97 inhibition with Eeyarestatin 1 and DBeQ on the secretory apparatus of MMCs with the effects induced by the proteasome inhibitor bortezomib, and the effects caused by combined inhibition of p97 and the proteasome. We found that p97 inhibition elicits cellular responses that are different from those induced by proteasome inhibition, and that the responses differ considerably between MMC lines. Moreover, we found that dual inhibition of both p97 and the proteasome terminally disrupts ER configuration and intracellular protein metabolism in MMCs. Dual inhibition of p97 and the proteasome induced high levels of apoptosis in all of the MMC lines that we analysed, including bortezomib-adapted AMO-1 cells, and was also effective in killing primary MMCs. Only minor toxicity was observed in untransformed and non-secretory cells. Our observations highlight non-redundant roles of p97 and the proteasome in maintaining secretory homeostasis in MMCs and provide a preclinical conceptual framework for dual targeting of p97 and the proteasome as a potential new therapeutic strategy in multiple myeloma.","claims":[{"public_id":"cl_fb053f3e1dd5a374eb293bcb6aef0cff","status":"active","text":"Dual inhibition of p97 and the proteasome induces high levels of apoptosis in all analyzed multiple myeloma cell lines, including bortezomib-adapted AMO-1 cells.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_fb053f3e1dd5a374eb293bcb6aef0cff"},{"public_id":"cl_5ae8266bd2763ae677d7115bc2daea4b","status":"active","text":"Dual inhibition of p97 and the proteasome is effective in killing primary multiple myeloma cells while causing only minor toxicity in untransformed and non-secretory cells.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_5ae8266bd2763ae677d7115bc2daea4b"},{"public_id":"cl_19703952be0cbbe70450e14bd491cc1b","status":"active","text":"Dual inhibition of p97 and the proteasome terminally disrupts endoplasmic reticulum configuration and intracellular protein metabolism in multiple myeloma cells.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_19703952be0cbbe70450e14bd491cc1b"},{"public_id":"cl_801b14d5d39a20f3746359a12b4e715c","status":"active","text":"p97 and the proteasome have non-redundant roles in maintaining secretory homeostasis in multiple myeloma cells.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_801b14d5d39a20f3746359a12b4e715c"},{"public_id":"cl_2816ad4a74b307067a1e9bb4dbcd6c1b","status":"active","text":"p97 inhibition elicits cellular responses that differ from those induced by proteasome inhibition, and the responses vary considerably between multiple myeloma cell lines.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_2816ad4a74b307067a1e9bb4dbcd6c1b"}],"concepts":[{"public_id":"co_0ccfe9b2d0381ec2f999909c466c5bbb","status":"active","name":"endoplasmic reticulum configuration","description":"The structural organization of the endoplasmic reticulum within cells.","types":["cellular structure"],"aliases":["ER configuration"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0ccfe9b2d0381ec2f999909c466c5bbb"},{"public_id":"co_3d47143cc605dddca0c4a82fa14bca0e","status":"active","name":"multiple myeloma cells","description":"Malignant plasma cells used here as the biological system under study.","types":["cell type"],"aliases":["MMCs"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3d47143cc605dddca0c4a82fa14bca0e"},{"public_id":"co_8da02c2d5ed1e76f536d31006cb20207","status":"active","name":"p97 inhibition","description":"Pharmacological suppression of the p97 ATPase/VCP/Cdc48 protein.","types":["method","intervention"],"aliases":["VCP inhibition","Cdc48 inhibition"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8da02c2d5ed1e76f536d31006cb20207"},{"public_id":"co_907250b8d038452e1dca9055d118ba0d","status":"active","name":"dual inhibition of p97 and the proteasome","description":"Simultaneous pharmacological inhibition of p97 and the proteasome.","types":["combined intervention","method"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_907250b8d038452e1dca9055d118ba0d"},{"public_id":"co_addd8d5f6ba21bd66f7364116fbba35f","status":"active","name":"p97","description":"An ATPase also known as VCP or Cdc48 that participates in protein quality control and degradation pathways.","types":["protein","enzyme"],"aliases":["VCP","Cdc48"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_addd8d5f6ba21bd66f7364116fbba35f"},{"public_id":"co_ae6de13e6faf35ac1a00c7c85fb0a174","status":"active","name":"bortezomib-adapted AMO-1 cells","description":"A multiple myeloma cell line adapted to the proteasome inhibitor bortezomib.","types":["cell line"],"aliases":["AMO-1 cells"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ae6de13e6faf35ac1a00c7c85fb0a174"},{"public_id":"co_b522c60dede49ee8137d39fab903db87","status":"active","name":"proteasome inhibition","description":"Blockade of proteasome-mediated protein degradation.","types":["method","intervention"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b522c60dede49ee8137d39fab903db87"},{"public_id":"co_b7d652c1c355529a11beb39897890efd","status":"active","name":"primary multiple myeloma cells","description":"Patient-derived multiple myeloma cells used as primary tumor cells.","types":["cell type"],"aliases":["primary MMCs"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b7d652c1c355529a11beb39897890efd"},{"public_id":"co_c00763c0f6f3679a781bedc05c18284e","status":"active","name":"secretory homeostasis","description":"The balanced cellular maintenance of secretory pathway function and protein processing.","types":["cellular process"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c00763c0f6f3679a781bedc05c18284e"},{"public_id":"co_cf30d92a580e50b2f16d95d86b7ef09d","status":"active","name":"apoptosis","description":"Programmed cell death triggered in the treated cells.","types":["cell death process"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_cf30d92a580e50b2f16d95d86b7ef09d"},{"public_id":"co_e7a1b1bf4cfb1214582b8db6a293c2df","status":"active","name":"untransformed and non-secretory cells","description":"Non-cancerous or low-secretion control cells used to assess toxicity.","types":["control cell type"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e7a1b1bf4cfb1214582b8db6a293c2df"},{"public_id":"co_ef8466169aeb3d4003eb4f87bc1fed5c","status":"active","name":"intracellular protein metabolism","description":"Cellular processes governing protein synthesis, handling, and degradation inside cells.","types":["cellular process"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ef8466169aeb3d4003eb4f87bc1fed5c"},{"public_id":"co_fcf4db812be0461ea4325c7bd34505ab","status":"active","name":"proteasome","description":"A protein degradation complex responsible for degrading ubiquitinated proteins.","types":["protein complex","degradation machinery"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fcf4db812be0461ea4325c7bd34505ab"}],"external_ids":{"DOI":"10.1371/journal.pone.0074415","ArXiv":null,"PubMed":24069311,"PubMedCentral":"3775786","MAG":2125542684,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0074415&type=printable","landing_url":"https://www.semanticscholar.org/paper/cfba141d239deb4bdb4989fdae0a91e6d7816225","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631856,"paper_uid":"2fc5d8ec-ac13-4e79-8e73-f6341d3517d3","canonical_identity":{"paper_id":631856,"paper_uid":"2fc5d8ec-ac13-4e79-8e73-f6341d3517d3","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/18238751"}